Last updated: April 23, 2026
DAPSONE: Who Supplies It (Active Ingredient and Finished Product Sources)
What is DAPSONE supplied as?
DAPSONE (dapsone) is supplied in two primary commercial forms:
- Active pharmaceutical ingredient (API): dapsone bulk drug substance.
- Finished dosage forms: most commonly tablets (and in some markets, other oral formats), manufactured using the dapsone API.
Which companies supply dapsone APIs?
The global dapsone API supply chain is dominated by diversified chemical and generic API manufacturers. Common supplier categories include:
- Generic API manufacturers producing dapsone for multiple branded and generic tablet products
- Specialty anti-infective API suppliers (dapsone is an older, established anti-mycobacterial/anti-inflammatory agent)
Which companies supply finished DAPSONE tablets?
Finished DAPSONE tablets are supplied by:
- Generic pharmaceutical manufacturers distributing dapsone tablets under multiple labelers
- Branded product holders in markets where dapsone tablets remain on formulary
Regulatory sourcing signals: labelers and market entries
Pharmaceutical market entry for dapsone tablets typically shows up as:
- ANDA (or equivalent) labelers in the US
- National authorization holders in the EU and other jurisdictions
- Wholesaler/distributor listings tied to authorized manufacturers
Supply risk profile (practical for R&D and procurement)
Because dapsone is an established, off-patent molecule:
- API availability is usually broad, with multiple low-to-mid cost suppliers
- Quality and consistency depend more on regulatory track record and site-specific cGMP compliance than on proprietary IP constraints
- Price and lead times can shift materially when any single supplier’s production capacity or inspection status changes
What is the procurement baseline for DAPSONE?
API: typical procurement requirements
When sourcing dapsone API for development or commercial production, the procurement baseline usually includes:
- Drug substance specification package (identity, assay, impurity profile, residual solvents if applicable)
- CoA and batch traceability for each lot
- Regulatory documentation (DMF or equivalent dossier, depending on jurisdiction)
- GMP manufacturing site documentation (compliance evidence and audit history)
Finished products: typical procurement requirements
For tablets, procurement typically requires:
- Marketing authorization evidence (country-specific)
- GMP and GDP documentation for the supply chain
- Lot-level CoA and stability information
- Packaging and labeling compliance with destination-market requirements
Key Takeaways
- DAPSONE is supplied as both dapsone API and dapsone tablets.
- Supply is generally multi-sourced due to long commercial history and generic availability.
- Procurement success for R&D or commercial production depends on site-specific API quality and compliance documentation more than on exclusivity or IP.
FAQs
1) Is dapsone available from multiple API suppliers?
Yes. As an established, off-patent drug, dapsone API is generally available from multiple generic API manufacturers.
2) Are DAPSONE tablets widely available as generics?
Yes. Dapsone tablets are commonly marketed as generics in many countries where dapsone remains in use.
3) What matters most when qualifying an API supplier for dapsone?
Batch-to-batch impurity control, CoA quality, and evidence of GMP compliance at the specific manufacturing site.
4) Can the API and finished product come from different suppliers?
Yes. Finished tablet manufacturers frequently source dapsone API from one or more qualified API suppliers.
5) Is supply continuity a major concern for dapsone?
Generally not at the molecule level, but continuity can still be impacted by individual supplier capacity, inspections, or batch availability.
References
[1] FDA. Drug Approval Packages. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA. Human medicines: marketing authorisation information. https://www.ema.europa.eu/en/human-medicines
[3] DailyMed (US FDA label database). https://dailymed.nlm.nih.gov/dailymed/
[4] WHO. WHO Drug Information (general reference for procurement and medicine information). https://www.who.int/publications/i/publication-seri ies/drug-information
